In this large, population‐based series of CRC patients, we have shown that mutational subgroups, based on the observed mutation frequencies of RAS (KRAS, NRAS, HRAS), BRAF, PIK3CA, and MET, as well as patients' MMR status, are associated with important differences in survival. This evidence concerns the gene KRAS and colorectal carcinoma.